A Phase II Randomized, Cross-Over, Double-Blinded, Placebo-Controlled Trial of the Farnesyltransferase Inhibitor R115777 in Pediatric Patients With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Tipifarnib (Primary)
- Indications Cancer; Neurofibromatoses; Neurofibromatosis 1; Plexiform neurofibroma
- Focus Adverse reactions; Therapeutic Use
- 15 Nov 2010 Actual end date changed from Mar 2010 to Nov 2010 as reported by ClinicalTrials.gov.
- 15 Nov 2010 Actual end date changed from Mar 2010 to Nov 2010 as reported by ClinicalTrials.gov.
- 15 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.